Analysts Lift Targets to $245–$320 as Q3 Revenue Hits $5.34 B
Lam Research reported Q3 revenue of $5.34 billion (up 22.1% y/y) and EPS of $1.27, beating estimates by $0.10 with a 30.2% net margin. Bank of America, JPMorgan and Cantor Fitzgerald raised their price targets to $245, $300 and $320 respectively, as Wallace Hart LLC added 8,671 shares valued at $1.16 million.
1. Robust Quarterly Results Highlight Growth Momentum
Lam Research reported EPS of $1.27 for the quarter, beating consensus by $0.10, on revenue of $5.34 billion, up 22.1% year-over-year. The company’s net margin reached 30.2%, driven by strong demand for deposition and etch tools used in advanced-node logic and 3D NAND production. Return on equity stood at 62.8%, reflecting operational efficiency gains. Management reiterated guidance of $1.25–1.45 EPS for the fiscal third quarter, underpinned by a healthy backlog and accelerating semiconductor capital spending trends. These results underscore Lam’s ability to capitalize on technology inflections and support chipmakers’ needs for smaller, faster devices.
2. Strategic Leadership Appointments To Accelerate AI-Era Execution
Effective March 6, 2026, Lam elevated Sesha Varadarajan to Chief Operating Officer, adding oversight of customer support, corporate strategy and government affairs to his global product portfolio remit. Varadarajan’s prior role drove rapid innovation in deposition and etch intensity during recent technology inflections. Karthik Rammohan will expand his responsibilities as Senior Vice President, Global Operations and Enterprise Solutions, overseeing manufacturing, supply chain, IT systems and quality. These appointments aim to increase operational velocity across product development, manufacturing and service delivery, positioning Lam to outpace peers as AI-driven semiconductor demand intensifies.
3. Institutional Investors and Insider Activity Signal Confidence
In the most recent 13F filings, Wallace Hart LLC established an $1.16 million stake, representing 0.9% of its portfolio, while IMG Wealth Management and Howard Hughes Medical Institute added new positions valued at $26,000 and $27,000 respectively. Overall, institutional ownership accounts for 84.6% of shares outstanding. On the insider front, the CFO sold 40,080 shares at an average price of $150.60, reducing their holding by 3.9% yet retaining over 987,000 shares. Analysts have raised target prices—from $195 to $245 at Bank of America and from $165 to $300 at JPMorgan—while maintaining buy or overweight recommendations, reflecting broad optimism about Lam’s market position and growth prospects.